Federal Practitioner

Supplement

Managing Advanced Renal Cell Carcinoma

Girindra Raval, MD, Swetha Gujja, MD, Paulette Mehta, MD, MPH, Adam C. Reese, MD, Jared M. Whitson, MD, Badrinath R. Konety, MD, Anjali Sibley, MD, Moben Mirza, MD, Peter J. Van Veldhuizen, MD, Nisreen Haideri, MD, Sean Keefe, PharmD, BCOP, and Cece Atherton, MSN, AOCN, ARNP

Fed Pract. 2009;26(suppl 4):1–22.

This supplement to Federal Practitioner on renal cell carcinoma (RCC), supported by Pfizer Inc, was developed with the aim of helping primary care providers in federal practice (especially those within the VA health care system) provide the highest quality care to their patients with RCC. It is our hope that, after reading this supplement, you will be better prepared to:

• Identify patients at risk for RCC and know when to consider screening measures.
• Recognize the signs and symptoms of RCC and refer the patient for appropriate imaging studies and other testing.
• Understand the systems used to stage and grade RCC.
• Discuss the options available for treating both early-stage and advanced RCC and their appropriate uses according to distinct patient and disease characteristics.
• Educate patients about the potential adverse effects of various treatments for advanced disease and apply appropriate monitoring.

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Quadrant HealthCom Inc., the U.S. government, or any of its agencies. Pfizer Inc provided limited editorial input. Some of the drugs or classes of drugs discussed in this supplement may not be listed on the VA national formulary or the DoD basic core formulary or addressed in VHA or DoD treatment guidelines. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients. Pazopanib (Votrient; GlaxoSmithKline, London, United Kingdom), an oral tyrosine kinase inhibitor, received FDA approval during the development of this supplement. Therefore data for this product is not included in the overview of available treatments.

[ PDF | Add to My Archive ]